Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2021-11-22
DOI
10.1080/13543784.2022.2009456
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted Treatment of Triple-Negative Breast Cancer
- (2021) Joanna A. Young et al. CANCER JOURNAL
- A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
- (2021) A. Brufsky et al. ANNALS OF ONCOLOGY
- Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
- (2021) Alessandro Rizzo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
- (2021) Alessandro Rizzo et al. Future Oncology
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
- (2021) Sara M. Tolaney et al. CLINICAL CANCER RESEARCH
- Novel therapies emerging in oncology to target the TGF-β pathway
- (2021) Byung-Gyu Kim et al. Journal of Hematology & Oncology
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
- (2021) Alessandro Rizzo et al. Immunotherapy
- Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities
- (2021) Laura M. Spring et al. ONCOLOGIST
- Antibody-Drug Conjugates Used in Breast Cancers
- (2021) Aram J. Abbas et al. Journal of Oncology
- Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
- (2021) E. Adams et al. ESMO Open
- Atezolizumab for the treatment of breast cancer
- (2020) Sangeetha M. Reddy et al. Expert Review of Anticancer Therapy
- PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
- (2020) Heng Zhu et al. Molecular Cancer
- Immunotherapeutic approaches for small-cell lung cancer
- (2020) Wade T. Iams et al. Nature Reviews Clinical Oncology
- Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
- (2020) Mónica Álvarez-Fernández et al. CANCER CELL
- Role of Immunotherapy in Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. Journal of the National Comprehensive Cancer Network
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) Changhoon Yoo et al. Journal for ImmunoTherapy of Cancer
- Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
- (2020) Praveen Vikas et al. Frontiers in Oncology
- Pancreatic cancer
- (2020) Jonathan D Mizrahi et al. LANCET
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
- (2020) Jackie E. Bader et al. MOLECULAR CELL
- Moving Immune Therapy Forward Targeting TME
- (2020) Kayla F Goliwas et al. PHYSIOLOGICAL REVIEWS
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
- (2020) Byoung Chul Cho et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
- (2020) Debora de Melo Gagliato et al. BIODRUGS
- Pembrolizumab and atezolizumab in triple-negative breast cancer
- (2020) Dorota Kwapisz CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antibody-Drug Conjugates in Metastatic Triple Negative Breast Cancer: A Spotlight on Sacituzumab govitecan, Ladiratuzumab vedotin, and Trastuzumab deruxtecan
- (2020) Julia E. McGuinness et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- TGFβ-Directed Therapeutics: 2020
- (2020) Beverly A. Teicher PHARMACOLOGY & THERAPEUTICS
- Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
- (2020) Angela Dalia Ricci et al. Cancer Control
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
- (2020) Angela Dalia Ricci et al. ESMO Open
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- The Role of CDK4/6 Inhibitors in Breast Cancer
- (2019) Conleth G. Murphy CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
- (2019) Stergios Boussios et al. Diagnostics
- An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme
- (2019) Yunyun Liu et al. ONCOGENE
- Targeted Therapies for Triple-Negative Breast Cancer
- (2019) Tomas G. Lyons CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
- (2019) E. Krasniqi et al. Journal of Hematology & Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- PARP Inhibition in Cancer: An Update on Clinical Development
- (2019) Esha Sachdev et al. Targeted Oncology
- Triple negative breast cancer: A thorough review of biomarkers
- (2019) Jesse Lopes da Silva et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
- (2018) Anita A. Turk et al. CANCER
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic and triple-negative breast cancer: challenges and treatment options
- (2018) Sumayah Al-Mahmood et al. Drug Delivery and Translational Research
- Genetic Markers in Triple-Negative Breast Cancer
- (2018) Zuzana Sporikova et al. Clinical Breast Cancer
- Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.
- (2018) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
- (2018) Shom Goel et al. TRENDS IN CELL BIOLOGY
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
- (2018) Mark L. Zangardi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The clinical promise of immunotherapy in triple-negative breast cancer
- (2018) Praveen Vikas et al. Cancer Management and Research
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy
- (2017) Hua Zheng et al. Immunotherapy
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
- (2016) J. M. Pitt et al. ANNALS OF ONCOLOGY
- High-mobility group AT-hook protein 2 expression and its prognostic significance in MGMT methylated and unmethylated glioblastoma
- (2016) FRANK P. SCHWARM et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- An overview of triple-negative breast cancer
- (2015) Pankaj Kumar et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Immunogenic cell death
- (2015) Abhishek D. Garg et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started